Treatment with SRC inhibitors and autophagy inducers exhibited synergism invitro, in ovo and in patient-derived tumor organoids with BAP1 loss, paving the way for treating BAP1-deficient cancers with autophagy inducers and kinase inhibitors. The gene discussed is SRC; the disease is neoplasm.